RU2353358C2 - Производные прегабалина для лечения приливов - Google Patents

Производные прегабалина для лечения приливов Download PDF

Info

Publication number
RU2353358C2
RU2353358C2 RU2005118081/14A RU2005118081A RU2353358C2 RU 2353358 C2 RU2353358 C2 RU 2353358C2 RU 2005118081/14 A RU2005118081/14 A RU 2005118081/14A RU 2005118081 A RU2005118081 A RU 2005118081A RU 2353358 C2 RU2353358 C2 RU 2353358C2
Authority
RU
Russia
Prior art keywords
hot flush
treatment
medicine
flush treatment
acid
Prior art date
Application number
RU2005118081/14A
Other languages
English (en)
Other versions
RU2005118081A (ru
Inventor
Дэвид Джеймс ДУЛИ (US)
Дэвид Джеймс ДУЛИ
Чарльз Прайс Мл. ТЭЙЛОР (US)
Чарльз Прайс Мл. ТЭЙЛОР
Эндрю Джон ТОРП (US)
Эндрю Джон Торп
Дэвид Юрген ВУСТРОУ (US)
Дэвид Юрген Вустроу
Original Assignee
Уорнер-Ламберт Компани Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32600153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2353358(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уорнер-Ламберт Компани Ллс filed Critical Уорнер-Ламберт Компани Ллс
Publication of RU2005118081A publication Critical patent/RU2005118081A/ru
Application granted granted Critical
Publication of RU2353358C2 publication Critical patent/RU2353358C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретение относится к медицине, в частности к лечению приливов у млекопитающих, в том числе у человека. Способ включает введение в организм пациента (3S,5R)-3-аминометил-5-метилоктановой кислоты или ее фармацевтически приемлемой соли в эффективном количестве. Способ обеспечивает лечение умеренных и тяжелых вазомоторных симптомов, в том числе в постменопаузный период у женщин, за счет преимущественной высокой активности кислоты в качестве альфа-2-дельта лиганда.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134

Claims (1)

  1. Способ лечения приливов у млекопитающих, в том числе у человека, включающий введение указанному млекопитающему терапевтически эффективного количества (3S,5R)-3-аминометил-5-метилоктановой кислоты или ее фармацевтически приемлемой соли.
RU2005118081/14A 2002-12-13 2003-12-03 Производные прегабалина для лечения приливов RU2353358C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43349102P 2002-12-13 2002-12-13
US60/433,491 2002-12-13
US48774003P 2003-07-16 2003-07-16
US60/487,740 2003-07-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2008140653/15A Division RU2008140653A (ru) 2002-12-13 2008-10-13 Производные прегабалина для лечения фибромиалгии и других расстройств

Publications (2)

Publication Number Publication Date
RU2005118081A RU2005118081A (ru) 2006-01-20
RU2353358C2 true RU2353358C2 (ru) 2009-04-27

Family

ID=32600153

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2005118081/14A RU2353358C2 (ru) 2002-12-13 2003-12-03 Производные прегабалина для лечения приливов
RU2008140653/15A RU2008140653A (ru) 2002-12-13 2008-10-13 Производные прегабалина для лечения фибромиалгии и других расстройств

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2008140653/15A RU2008140653A (ru) 2002-12-13 2008-10-13 Производные прегабалина для лечения фибромиалгии и других расстройств

Country Status (15)

Country Link
US (1) US20090203782A1 (ru)
EP (2) EP2172197A1 (ru)
JP (1) JP2006513257A (ru)
KR (1) KR20050085636A (ru)
CN (1) CN101862317A (ru)
AU (1) AU2003303040B2 (ru)
BR (1) BR0317253A (ru)
CA (1) CA2505788A1 (ru)
MX (1) MXPA05006320A (ru)
NO (1) NO20052264L (ru)
NZ (1) NZ540591A (ru)
PL (1) PL377520A1 (ru)
RU (2) RU2353358C2 (ru)
TW (1) TW200423925A (ru)
WO (1) WO2004054566A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089289A2 (en) 2003-03-31 2004-10-21 Xenoport, Inc. Treating or preventing hot flashes using prodrugs of gaba analogs
JP2007505095A (ja) * 2003-09-12 2007-03-08 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー うつ病及び不安障害の治療のためのアルファ−２−デルタリガンド及びｓｓｒｉ及び／又はｓｎｒｉを含む組み合わせ
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
KR101900584B1 (ko) 2014-02-03 2018-09-19 콰드리가 바이오사이언시스 인코포레이티드 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체
JP6271766B2 (ja) * 2014-02-03 2018-01-31 クワドリガ バイオサイエンシーズ， インコーポレイテッド 化学療法剤としてのβ置換γアミノ酸および類似体
TWI665178B (zh) 2015-08-03 2019-07-11 夸德里加生物科學公司 作為化療劑的β－取代的β－氨基酸和類似物及其應用
CN115739134B (zh) * 2022-11-24 2024-08-02 贵州大学 一种利用三氯化钌废弃物制备氯乙烯合成用复合催化剂的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
RU94046105A (ru) 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EP0959074A3 (en) 1992-12-17 2000-06-07 Pfizer Inc. Substituted pyrazoles as CRF antagonists
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
KR0170567B1 (ko) 1992-12-17 1999-02-18 알렌 제이. 스피겔 부신피질자극호르몬-유리 인자 길항물질 활성을 갖는 피라졸 및 피라졸로피리미딘
DK0674641T3 (da) 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
US5670539A (en) * 1993-07-21 1997-09-23 New York State Office Of Mental Health Treatment of movement disorders using large neutral amino acids
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
KR100491282B1 (ko) * 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
EP0937032B1 (en) 1996-10-23 2007-05-09 Warner-Lambert Company LLC Substituted gamma aminobutyric acids as pharmaceutical agents
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
BR9813284B1 (pt) 1997-10-27 2012-08-21 aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos e composição farmacêutica.
PL345338A1 (en) 1998-07-09 2001-12-17 Warner Lambert Co Method for the treatment of insomnia
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1169060B1 (en) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
MXPA01012319A (es) 1999-06-10 2002-07-22 Warner Lambert Co Acidos 3-propil gama aminobutiricos mono y disubstituidos.
US6642398B2 (en) * 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1202725B1 (en) * 1999-07-22 2007-04-11 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
SK286227B6 (sk) * 2001-05-25 2008-05-06 Warner-Lambert Company Llc Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOIRA CONNOL. Предменструальный синдром: новое в определении, диагностике и ведении больных. Advances in Psychiatric Treatment, 2001, vol.7, p.469-477. *
Руководство по климактерию. / Под ред. В.П.Сметник и др. - М.: МИА, 2001, с.361-372. *

Also Published As

Publication number Publication date
CA2505788A1 (en) 2004-07-01
EP1572188A1 (en) 2005-09-14
NZ540591A (en) 2008-03-28
TW200423925A (en) 2004-11-16
US20090203782A1 (en) 2009-08-13
EP2172197A1 (en) 2010-04-07
JP2006513257A (ja) 2006-04-20
RU2008140653A (ru) 2010-04-20
NO20052264L (no) 2005-09-12
CN101862317A (zh) 2010-10-20
KR20050085636A (ko) 2005-08-29
NO20052264D0 (no) 2005-05-10
AU2003303040A1 (en) 2004-07-09
RU2005118081A (ru) 2006-01-20
WO2004054566A1 (en) 2004-07-01
AU2003303040B2 (en) 2009-04-23
MXPA05006320A (es) 2005-08-26
PL377520A1 (pl) 2006-02-06
BR0317253A (pt) 2005-11-01

Similar Documents

Publication Publication Date Title
US11786496B2 (en) Composition and methods for treating intestinal hyperpermeability
EP3238707B1 (en) Compositions and methods for treating intestinal hyperpermeability
RU2005131995A (ru) Композиции, содержащие жирные кислоты и аминокислоты
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
EA200501023A1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
RU2009101324A (ru) Композиции и способы лечения воспаления слизистой оболочки
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
CN107835695B (zh) 用于治疗自闭症的组合物和方法
RU2006141647A (ru) Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний
JP2008127369A (ja) 外分泌障害を処置するための医薬
RU2353358C2 (ru) Производные прегабалина для лечения приливов
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
RU2016137926A (ru) Композиции грапипранта и способы их применения
JP6100510B2 (ja) 抗感冒剤
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
RU2006126471A (ru) Способ лечения воспалительных заболеваний слюнных желез
TWI527828B (zh) 新穎的三萜化合物及其用途
BRPI0415111A (pt) composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético
RU2290188C2 (ru) Способ лечения воспалительных и реактивно-дистрофических заболеваний больших слюнных желез
Melnik et al. Pharmacological research of the dental gel with carbon dioxide Humulus lupulus extract
CA2598786A1 (en) Composition and method for increasing the anabolic state of muscle cells
RU2006138429A (ru) Противовоспалительные лактоны
UA124508U (uk) Спосіб лікування хронічного альвеоліту
RU2009125509A (ru) Способ лечения больных с гнойно-воспалительными заболеваниями кожи

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20101204